209 related articles for article (PubMed ID: 21118980)
1. As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Mao JH; Sun XY; Liu JX; Zhang QY; Liu P; Huang QH; Li KK; Chen Q; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21683-8. PubMed ID: 21118980
[TBL] [Abstract][Full Text] [Related]
2. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Wang T; Wen T; Li H; Han B; Hao S; Wang C; Ma Q; Meng J; Liu J; Xu H
Int J Nanomedicine; 2019; 14():5581-5594. PubMed ID: 31413564
[TBL] [Abstract][Full Text] [Related]
3. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Wu J; Meng F; Lu H; Kong L; Bornmann W; Peng Z; Talpaz M; Donato NJ
Blood; 2008 Apr; 111(7):3821-9. PubMed ID: 18235045
[TBL] [Abstract][Full Text] [Related]
4. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia.
Zhang QY; Mao JH; Liu P; Huang QH; Lu J; Xie YY; Weng L; Zhang Y; Chen Q; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3378-83. PubMed ID: 19208803
[TBL] [Abstract][Full Text] [Related]
5. [Role and Mechanism of the Interaction of BCR-ABL with E3 Ligase c-CBL in Targeting Therapy of Chronic Myelogenous Leukemia].
Mao JH; Huang QH; Liu P; Luo C; Xi XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):42-49. PubMed ID: 28245373
[TBL] [Abstract][Full Text] [Related]
6. Bag1 directly routes immature BCR-ABL for proteasomal degradation.
Tsukahara F; Maru Y
Blood; 2010 Nov; 116(18):3582-92. PubMed ID: 20675402
[TBL] [Abstract][Full Text] [Related]
7. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide.
Goussetis DJ; Gounaris E; Wu EJ; Vakana E; Sharma B; Bogyo M; Altman JK; Platanias LC
Blood; 2012 Oct; 120(17):3555-62. PubMed ID: 22898604
[TBL] [Abstract][Full Text] [Related]
8. RAPSYN-mediated neddylation of BCR-ABL alternatively determines the fate of Philadelphia chromosome-positive leukemia.
Zhao M; Dai B; Li X; Zhang Y; Qiao C; Qin Y; Li Z; Li Q; Wang S; Yang Y; Chen Y
Elife; 2024 Jun; 12():. PubMed ID: 38865175
[TBL] [Abstract][Full Text] [Related]
9. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Lee J; Shen P; Zhang G; Wu X; Zhang X
Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
[TBL] [Abstract][Full Text] [Related]
10. Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein.
Shibata N; Ohoka N; Hattori T; Naito M
Chem Pharm Bull (Tokyo); 2019; 67(3):165-172. PubMed ID: 30827996
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
12. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
[TBL] [Abstract][Full Text] [Related]
13. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
14. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
15. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Roy M; Sarkar R; Mukherjee A; Mukherjee S
Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
[TBL] [Abstract][Full Text] [Related]
17. p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl.
Salgia R; Sattler M; Pisick E; Li JL; Griffin JD
Exp Hematol; 1996 Feb; 24(2):310-3. PubMed ID: 8641358
[TBL] [Abstract][Full Text] [Related]
18. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
J Biol Chem; 1995 Sep; 270(37):21468-71. PubMed ID: 7545163
[TBL] [Abstract][Full Text] [Related]
19. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
O'Dwyer M
Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
[TBL] [Abstract][Full Text] [Related]
20. Single amino acid-based PROTACs trigger degradation of the oncogenic kinase BCR-ABL in chronic myeloid leukemia (CML).
Zhang J; Ma C; Yu Y; Liu C; Fang L; Rao H
J Biol Chem; 2023 Aug; 299(8):104994. PubMed ID: 37392851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
